Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A

4(80.0%)

Phase 3

1(20.0%)

5Total

N/A(4)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07539584Not ApplicableCompleted

Adiponectin in Patients With Metabolic Disorders

Role: collaborator

NCT07538908Active Not Recruiting

Superselective Renal Artery Embolization for Renal Angiomyolipoma

Role: lead

NCT07404358Phase 3Active Not Recruiting

Dalargin for Prevention of Organ Disfunction in High-Risk Abdominal Surgery

Role: lead

NCT07123909Not ApplicableRecruiting

Studies on Adsorption International Learning Initiative Global

Role: lead

NCT07056595Not ApplicableRecruiting

Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial

Role: lead

NCT05339204Not ApplicableUnknown

The Role of Allo-HSCT in MRD-negative Patients With AML Under the Age of 60 Years in the First Complete Remission

Role: collaborator

All 6 trials loaded